"Triazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.
| Descriptor ID |
D014227
|
| MeSH Number(s) |
D03.383.931
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazines".
Below are MeSH descriptors whose meaning is more specific than "Triazines".
This graph shows the total number of publications written about "Triazines" by people in this website by year, and whether "Triazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 3 | 6 |
| 2021 | 5 | 5 | 10 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazines" by people in Profiles.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
-
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Adv. 2024 05 28; 8(10):2509-2519.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leuk Res. 2024 05; 140:107497.
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
IDH2 mutations in acute myeloid leukemia. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1733-1741.
-
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun; 2(6):EVIDoa2200339.
-
Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.
-
Synthesis of 1,2,3-Triazine Derivatives by Deoxygenation of 1,2,3-Triazine 1-Oxides. Org Lett. 2022 09 16; 24(36):6543-6547.